Fate Therapeutics (FATE) Net Cash Flow (2012 - 2026)

Fate Therapeutics has reported Net Cash Flow for 15 years, with the latest figure at -$7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 181.62% year-over-year to -$7.2 million; the trailing twelve-month figure through Mar 2026 stood at -$5.5 million (up 93.21% YoY), and the FY2025 full-year result was $10.6 million, up 198.22% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$7.2 million, down from $6.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $79.5 million in Q1 2024, with the low at -$84.4 million in Q2 2024.
• Historically, Net Cash Flow has averaged -$5.8 million across 5 years, with a median of -$3.7 million in 2025.
• The largest YoY upside for Net Cash Flow was 511.39% in 2024 against a maximum downside of 1883.71% in 2024.
• Fate Therapeutics' Net Cash Flow stood at -$20.8 million in 2022, then jumped by 141.12% to $8.5 million in 2023, then plunged by 121.71% to -$1.9 million in 2024, then jumped by 424.12% to $6.0 million in 2025, then slumped by 220.46% to -$7.2 million in 2026.
• The last three Net Cash Flow figures came in at -$7.2 million (Q1 2026), $6.0 million (Q4 2025), and -$627000.0 (Q3 2025), per Business Quant data.